XLRN Acceleron Pharma Inc.

41.92
+1.66  (+4%)
Previous Close 40.26
Open 40.41
Price To Book 4.43
Market Cap 2,214,784,680
Shares 52,833,604
Volume 236,376
Short Ratio
Av. Daily Volume 269,882
Stock charts supplied by TradingView

NewsSee all news

  1. Acceleron Announces Topline Results from the Phase 2 Trial of ACE-083 in Patients with Facioscapulohumeral Muscular Dystrophy

    – ACE-083 did not achieve statistically significant improvements in functional endpoints relative to placebo – – Acceleron to discontinue development of ACE-083 in facioscapulohumeral muscular dystrophy – – Topline

  2. Acceleron Receives FDA Orphan Drug Designation for Sotatercept in Pulmonary Arterial Hypertension

    Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that the United States

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 data due 1Q 2020.
Sotatercept - PULSAR
Pulmonary arterial hypertension (PAH)
Phase 3 trial initiated - noted October 30, 2018.
Luspatercept - COMMANDS
First-line, lower-risk Myelodysplastic syndromes (MDS)
Phase 2 data 2H 2019.
Luspatercept
Myelofibrosis
Phase 2 data due 1Q 2020.
ACE-083
Charcot-Marie-Tooth disease (CMT)
PDUFA date April 4, 2020.
Luspatercept
Myelodysplastic syndromes (MDS) cancer
Phase 2 updated data at ASH 2016.
Luspatercept
Low or intermediate-risk MDS patients who are erythropoiesis-stimulating agent (ESA) naïve or ring sideroblast negative (RS-)
Phase 2 data did not achieve statistically significant improvements in functional endpoints relative to placebo - September 16, 2019.
ACE-083
Facioscapulohumeral muscular dystrophy
Phase 2 data released June 12, 2017 - primary endpoint not met.
Dalantercept - DART Study
Renal Cell Carcinoma (RCC) - cancer
Phase 2 updated data at ASCO June 2018. 55% achieved a clinically meaningful erythroid improvement.
Luspatercept Extension Study - PACE-MDS
Myelodysplastic Syndromes
Announced April 4, 2019 intention to discontinue development.
ACE-2494
Healthy volunteers
Phase 2 data due YE 2020.
Luspatercept - BEYOND
Non-transfusion-dependent beta-thalassemia
PDUFA date December 4, 2019 under priority review.
Luspatercept
Beta-thalassemia
Phase 2 exploratory trial data due 2020.
Sotatercept - SPECTRA
Pulmonary arterial hypertension (PAH)

Latest News

  1. Acceleron Announces Topline Results from the Phase 2 Trial of ACE-083 in Patients with Facioscapulohumeral Muscular Dystrophy

    – ACE-083 did not achieve statistically significant improvements in functional endpoints relative to placebo – – Acceleron to discontinue development of ACE-083 in facioscapulohumeral muscular dystrophy – – Topline

  2. Acceleron Receives FDA Orphan Drug Designation for Sotatercept in Pulmonary Arterial Hypertension

    Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that the United States